Schwartz Center Receives $500,000 Grant from the Amgen Foundation

AmgenThe Schwartz Center for Compassionate Healthcare, a Boston-based nonprofit dedicated to strengthening the relationship between patients and their healthcare providers, today announced it has received a $500,000 grant from the Amgen Foundation. This grant will go toward the planned expansion of Schwartz Center Rounds® and to support the launch of a National Consensus Project.

These initiatives aim to make compassionate, patient-centered care a national healthcare priority. The Schwartz Center Rounds allow caregivers from multiple disciplines to come together on a regular basis to discuss the most challenging emotional and social issues they face in caring for patients. The National Consensus Project will convene a broad range of stakeholders to define compassionate care, develop best practices to ensure that this type of care is provided, and develop a plan to implement these core principles and best practices.

"This grant, the largest in our history, will make it possible for us to double the number of Rounds sites overall in California and the Washington, D.C. area and to expand the program to additional cancer centers throughout the United States," said Julie Rosen, executive director, Schwartz Center. "It will also allow us to launch our National Consensus Project to ensure that all patients receive compassionate care something that is particularly important now as our healthcare system is changing and providers are under such intense pressure to reduce costs, while improving quality."

The Amgen Foundation, based in Thousand Oaks, is the philanthropic arm of Amgen, the world's largest biotechnology company. A key area of focus for the Foundation is ensuring quality of care and access for patients with an emphasis on patient empowerment and reducing healthcare disparities.

"The Schwartz Center provides health professionals with a practical avenue to reflect upon and manage through the complexities inherent in providing care for seriously ill patients," said Jean Lim Terra, president, Amgen Foundation. "We are proud to support these programs that empower healthcare professionals to truly fulfill their mission to deliver quality care for patients."

Schwartz Center Rounds are currently held at 247 hospitals and other healthcare institutions in 35 states in the United States (U.S.) and at 11 hospitals in the United Kingdom. A comprehensive evaluation has shown that caregivers who attend multiple Rounds sessions feel more compassionate toward their patients and less stressed. Attendees also report that the program has improved teamwork and resulted in system changes.

Through its National Consensus Project, the Schwartz Center will launch a national conversation about the importance of compassionate care by convening healthcare professionals, patients, policymakers, educators and researchers to reach expert consensus on a definition of compassionate care, develop a set of organizational and institutional best practices to ensure that this type of care is provided, and develop a plan for disseminating these core principles and best practices.

According to Rosen, "Our vision is a healthcare system in which all patients receive compassionate, patient- and family-centered care, and all caregivers are supported to provide it. We are grateful to the Amgen Foundation for helping us to make this vision a reality."

The Schwartz Center's vision is based on the experience of Ken Schwartz, a well-known Boston healthcare attorney who died of lung cancer at the age of 40 and found that what mattered to him most as a patient was the compassionate care he received from his caregivers, which he wrote in the Boston Globe Magazine "made the unbearable bearable." He founded the Schwartz Center in 1995 to ensure that all patients receive compassionate care.

In a national survey conducted by the Schwartz Center in 2010, more than 80 percent of patients said they believe that effective communication and emotional support the essential elements of compassionate care make a difference in how well patients recover from illness and can even make a difference in whether a patient lives or dies. Yet, patients' ratings of how well their caregivers demonstrated these attributes fell short of their expectations and only about half of patients rated the U.S. healthcare system as a compassionate one.

The Amgen Foundation has been a long-time supporter of the Schwartz Center, having previously provided financial support for Schwartz Center Rounds in 2004 and then again in 2009.

About the Amgen Foundation
The Amgen Foundation seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made nearly $180 million in grants to local, regional, and national nonprofit organizations that impact society in inspiring and innovative ways. It has also supported disaster relief efforts both domestically and internationally.

About the Schwartz Center for Compassionate Healthcare
The Schwartz Center is a national nonprofit organization that develops and funds innovative programs to promote compassionate care, recognizes and honors caregivers who demonstrate extraordinary compassion in caring for patients and families, and supports policies that promote compassionate care. Its "Agenda for Improving Compassionate Care" was published in the September 2010 issue of Health Affairs, the nation's leading health policy journal. The Center is housed at Massachusetts General Hospital in Boston.

Most Popular Now

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

Nucala (mepolizumab) gains FDA approval for two ne…

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjec...

Jeff Settleman, Ph.D., joins Pfizer to lead Oncolo…

Pfizer Inc. (NYSE: PFE) announced that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading al...

Full data from CAROLINA® outcome trial support lon…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardio...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Cleveland researchers test novel gene therapy for …

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Bristol-Myers Squibb announces post-closing leader…

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with ...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Prescription drug costs steadily soar, yet price t…

After reviewing tens of millions of insurance claims for the country’s 49 most popular brand-name prescription drugs, a team from Scripps Research Translational Institute...